'Lansley must listen to nurses on the front line' NICE recommends infliximab and adalimumab for Crohn's disease treatment
In final draft guidance published today (4 March) NICE has recommended infliximab and adalimumab as treatment options for people with severe, active Crohn’s disease whose condition has not responded to conventional therapy, or who are intolerant of or have contraindications to conventional therapy.
You need to register to view this content
You now need to register for FREE to read our news. Please sign in or register to continue
- Registering is FREE and takes only two minutes
- Registering allows you to read our registered-only news, practice comments and access our Nursing Times Learning units.
- You'll also be able to sign up for our free newsletters
Already registered?
To check that you are registered please enter your email address below
Not registered?
Registration is free and takes just two minutes. After you register, you'll get access to our news stories, competitions and giveaways, newsletters and more.
Not activated?
If you are a registered subscriber you also need to activate your subscription in order to access your subscriber-only content online. This includes free learning units and practice articles.
